94038-16-1Relevant academic research and scientific papers
THERAPEUTIC INHIBITORS OF THE REVERSE MODE OF ATP SYNTHASE
-
, (2018/08/12)
Compounds of the following formula, and pharmaceutically-acceptable salts, solvates, hydrates and prodrugs thereof, formula (A) are useful to preferentially inhibit the ATP-hydrolysing mode of ATP synthase, and are thereby useful for treating various dise
N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F1F0 ATP hydrolase
Atwal, Karnail S.,Ahmad, Saleem,Ding, Charles Z.,Stein, Philip D.,Lloyd, John,Hamann, Lawrence G.,Green, David W.,Ferrara, Francis N.,Wang, Paulina,Rogers, W. Lynn,Doweyko, Lidia M.,Miller, Arthur V.,Bisaha, Sharon N.,Schmidt, Joan B.,Li, Ling,Yost, Kenneth J.,Lan, Hsi-Jung,Madsen, Cort S.
, p. 1027 - 1030 (2007/10/03)
A series of substituted guanidine derivatives were prepared and evaluated as potent and selective inhibitors of mitochondrial F1F0 ATP hydrolase. The initial thiourethane derived lead molecules possessed intriguing in vitro pharmacological profiles, though contained moieties considered non-drug-like. Analogue synthesis efforts led to compounds with maintained potency and superior physical properties. Small molecules in this series which potently and selectivity inhibit ATP hydrolase and not ATP synthase may have utility as cardioprotective agents.
N-substituted 1-aryl-2-(1H-imidazol-1-yl)-1-ethanamines with broad spectrum in vitro antimycobacterial and antifungal activities
Fioravanti, Rossella,Biava, Mariangela,Porretta, Giulio Cesare,Artico, Marino,Lampis, Giorgio,Deidda, Delia,Pompei, Raffaello
, p. 87 - 97 (2007/10/03)
Novel broad-spectrum in vitro antimycobacterial agents, namely N-(4-biphenyl-1-ylmethyl)-1-aryl-2-(1H-imidazol-1-yl)-1-ethanamines, are described. The new derivatives are also provided with in vitro antifungal activity against a variety of pathogenic fung
